First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma.

Autor:	Spasov NJ; Division of Pediatric Oncohematology, Department of Pediatrics and Medical Genetics, Medical University of Plovdiv, Plovdiv, Bulgaria., Dombrowski F; Institute of Pathology., Lode HN; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany., Spasova M; Division of Pediatric Oncohematology, Department of Pediatrics and Medical Genetics, Medical University of Plovdiv, Plovdiv, Bulgaria., Ivanova L; Division of Pediatric Oncohematology, Department of Pediatrics and Medical Genetics, Medical University of Plovdiv, Plovdiv, Bulgaria., Mumdjiev I; Division of Pediatric Oncohematology, Department of Pediatrics and Medical Genetics, Medical University of Plovdiv, Plovdiv, Bulgaria., Burnusuzov H; Division of Pediatric Oncohematology, Department of Pediatrics and Medical Genetics, Medical University of Plovdiv, Plovdiv, Bulgaria., Siebert N; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
Jazyk:	angličtina
Zdroj:	Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2022 Aug 01; Vol. 44 (6), pp. e948-e953. Date of Electronic Publication: 2022 May 27.
DOI:	10.1097/MPH.0000000000002488
Abstrakt:	Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. Here we report 3 cases with newly diagnosed, metastatic, GD2-positive ES or Ewing-like sarcoma treated with the anti-GD2 antibody dinutuximab beta in addition to standard chemotherapeutic regimens. Treatment was well-tolerated, and all patients achieved complete remission, without evidence of relapse. First-line anti-GD2 immunotherapy in patients with metastatic, GD2-positive ES or Ewing-like sarcoma represents a promising therapeutic option that warrants further clinical evaluation. Competing Interests: H.N.L. is a consultant of EUSA Pharma. The remaining authors declare no conflict of interest. (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu